Blood Cancer Journal, published by SPRINGERNATURE, is a leading open-access journal that has been at the forefront of hematology and oncology research since its inception in 2011. With an impressive impact factor and a commitment to disseminating high-quality research, it holds a prestigious Q1 ranking in both hematology and oncology categories as of 2023. The journal is dedicated to publishing innovative studies, comprehensive reviews, and insightful commentaries that advance our understanding of blood cancers, making it an essential resource for researchers, healthcare professionals, and students in the field. Its open-access model ensures that groundbreaking research is accessible to a global audience, promoting collaborative efforts to enhance treatment methodologies and patient outcomes. With a strong reputation illustrated by its Scopus rankings—8th in hematology and 30th in oncology—Blood Cancer Journal exemplifies excellence and leadership in the ever-evolving landscape of cancer research.

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

Cancer Discovery, published by the American Association for Cancer Research, stands as a vital resource in the oncological research community, renowned for its commitment to disseminating groundbreaking studies and innovative findings in cancer biology, prevention, diagnostics, and treatment. With a significant impact factor reflecting its esteemed position, this journal facilitates open discussions and collaborations, striving to bridge the gap between experimental and clinical research. The journal, which has been active since 2011, is classified as a Q1 publication in 2023, underscoring its influence and authority in the realm of Oncology. By providing a platform for rigorous peer-reviewed articles, Cancer Discovery aims to advance our understanding of cancer and enhance therapeutic strategies, making it an indispensable tool for researchers, professionals, and students eager to stay at the forefront of cancer research.

LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

HAEMATOLOGICA, published by FERRATA STORTI FOUNDATION, is a prestigious journal in the field of hematology, recognized for its high impact and contribution to advancing research in this critical area of medicine. With an impressive Q1 ranking in the 2023 category of Hematology and a notable Scopus rank of #12 out of 137, the journal serves as an essential platform for disseminating innovative studies, clinical trials, and comprehensive reviews from 1947 to 2024. Based in Italy, with a commitment to quality and academic integrity, HAEMATOLOGICA fosters collaboration among researchers, practitioners, and students interested in the latest developments and methodologies within hematological science. Although it does not offer open access, the journal ensures that valuable insights are accessible through institutional subscriptions, emphasizing its role in shaping the future of hematologic research.

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.

Leukemia Research is a prominent academic journal dedicated to advancing the field of hematology and oncology, focusing on the latest research developments related to leukemia and other hematological disorders. Founded in 1977 and published by Pergamon-Elsevier Science Ltd in the United Kingdom, this esteemed journal has established itself as a vital resource for researchers and clinicians alike. With an impressive impact factor and categorized in the top quartiles of Cancer Research and Hematology, it provides a platform for high-quality research articles, reviews, and clinical studies that contribute to a deeper understanding of leukemia's complexities. Although not an Open Access journal, Leukemia Research ensures widespread dissemination of knowledge crucial for developing innovative treatment strategies and improving patient outcomes. Researchers, professionals, and students in the fields of hematology and oncology will find this journal an invaluable asset in staying at the forefront of leukemia research, as it prepares to expand its impact through converged years of publication extending into 2024.

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.